Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.The analyst’s bullish view is centered around optimism associated with attractive opportunities for Vaxart’s ‘differentiated’ oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine.Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.“VX ...